• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A series of 1-piperidinophthalazine derivatives as phosphodiesterase inhibitors and cardiac stimulants.
    公开号:SU856383A3
    申请号:SU782624349
    申请日:1978-06-02
    公开日:1981-08-15
    发明作者:Фрейзер Кэмпбелл Саймон；Кристофер Данилевич Джон；Гарт Эванс Энтони；Лесли Хэм Аллан
    申请人:Пфаизер Корпорейшн (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new 1- (M-piperidino) phthalazine derivatives of the general formula in which k is a hydrogen atom; Y is the S 3 or 4 position of the Liléridine ring and denotes where C is C 4 alkyl alkyl alkoxy, M-COR, where R is C-C 4 alkyl, C. C-Alkoxyphenyl or benzylcoi RA is a hydrogen atom or C -Cd-alkyl -M-SOftR5, where a hydrogen atom or C-Cd-alkyl and R - C, -Cd-alkyl, phenyl, di C, -C4 alkoxy / phenyl, bey zyl or 2-. B- or 4-liridyl -N-CONJ R where R is a hydrogen atom or C -, - C4-alkyl; R is C-Cd-alkyl, benzyl or 2-, 3- or 4-pyridyl, and R is a hydrogen atom or alkyl. -OCONHR, where. C-Cd-alkyl, phenyl, benzyl or 2-, 3- or 4-pyridyl. - hydroxy,.-alkanoyloxy or C., - Sf-alkoxy, C-Su-alkyl, substituted by oxy-group,.-alkoxy or a group of formula where R each independently represents a hydrogen atom or C-Sdgalkyl, SL- C.-alkoxy, substituted in any position, except for the L-carbon atom, hydroxy-pear or C, -C-apkoxygroup, or their salts, which can be used 6 chemical-pharmaceutical industry. The interaction of pileridia with halogen derivatives tlJ is known. The purpose of the invention is to develop a method for the shaluza of new compounds of the production of & EX phthalazine, which have the property of smoothing out heart activity. The goal is achieved by the method of obtaining compounds of the above general formula I, which are obtained by reacting phthalase formulas.
    RI HjCO -.,
    JTjdO.
    h
    where ft is chlorine, bromine or piperidine atoms of general formula H
    Q,
    where Y is as defined above, and if Y is a group capable of replacing the ly group, Y is protected with a protecting group before the reaction, which is removed after the reaction, the resulting target products are isolated in free form or, if necessary, the compound of general formula I, wherein Y is hydroxy, is converted to a compound of the general formula T, wherein Y is OCONHR, where R values are given above, by reaction with an isocyanate, where R is different from a hydrogen atom, or to obtain a compound of general formula I, in which R is a hydrogen atom, with sodium or potassium cyanate in the presence of acid; or convert a compound of general formula I, where Y is OH, to a compound in which Y is a lower alkanoyloxy group, by acylation with a lower alkanoic acid anhydride or a lower alkanoyl chloride or bromide; or make a compound of general formula I, where Y is - (lower alkyl), into
    HE
    compound of general formula I, in which. Y is a group of the formula - (lower alkyl), by oxidation with chromium trioxide, and the target product is isolated.
    Compounds of the proposed method containing one or more asymmetric centers can exist as a mixture of enantiomers, and they can be separated into individual isomers by physical methods, for example, by fractional crystallization of free bases or corresponding salts, or by chromatography of free bases. From the pharmaceutical point of view, salts refer to salts containing anions, such as hydrochloride, hydrobromide, hydroiodide, sulfate or bisulfate, phosphate or acid phosphate, acetate, maleate, fumarate, lactate, tartrate, citrate, gluconate, saharit, and para-toluene. sulphonate. The cardiac stimulating activity of compounds of general formula T is measured by effectiveness when used in one or more of the following tests.
    1. Increase the degree of contraction of the remote, spontaneous pulsating system of the two atria of the guinea pig;
    2. An increase in the degree of myocardial contraction {dp / dt of the left ventricle) in an anesthetized dog with an implanted left ventricular catheter;
    3. Increase the degree of myocardial contraction in an awake dog with an implanted sensor in the left ventricle.
    In test 1, a positive inotropic and chronotropic atrial response is measured against several doses and compared with the corresponding reactions obtained using isoprenaline,
    In test 2, the positive inotropic response to the use of the test compound after its intravenous administration is measured on the anesthetized dog. The effectiveness of the inotropic agent, when applied to determine the effect on the frequency of contraction and the duration of exposure to obtain a positive inotropic effect, was determined by indirect indicators, for example, by measuring blood pressure.
    In test 3, positive inotrop-. The effect of the test compound is measured after its administration by the intravenous or oral route to a waking dog with an implanted sensor in the left ventricle. The effectiveness of the inotropic agent when used to determine the effect on the frequency of contraction and determine the duration of exposure to obtain a positive inotropic effect for the tested compound is determined by indirect indicators, for example, by measuring blood pressure.
    Example 1. Preparation of 6,7-dimethoxy-1-G4- {N-ethylcarbamoyloxy) piperidino-petalazin.
    1-Chloro-6,7-dimethoxyphthalazine {2.69 g) and 4- {ethylcarbamoyloxy) piperidine (4.3 g) is suspended in isoamyl alcohol (60 ml) 90 ° C for 18 hours. The mixture is filtered and the filtrate is evaporated to dryness under vacuum resulting in a brown oily liquid that, when triturated with ethyl acetate (30 ml) gives crystals, which are filtered. The solid obtained is dissolved in a minimum volume of boiling acetonitrile and after cooling the solution, crystals of unchanged 4- {ethylcarbamoyloxy) piperidine are formed (1 , 8 g). They are filtered, the filtrate is evaporated under vacuum to dryness. The crude product thus obtained is suspended in water (50 ml is neutralized with a 5N solution of sodium hydroxide solution to pH 10, extracted with chloroform 2x50 4 L) After drying the combined chloroform extracts over the beneficial sodium carbonate sodium chloroform is evaporated to dry on a vacuum, resulting in a brown color the oil is liquid, purified by separation into colonies with silica powder (ZON layer size 25 cm) using chloroform and 2% methanol in chloroform as Luiren solvent ofemom Eighteen fractions were collected in 40 ml; then the corresponding fractions (which are identified with g (omsen), etc., xx) are combined and dried (j), the result is a glassy product. It is dissolved in warm ethyl acetate (25 ml) (dry oxygen) T, diluted with excess the amount of ether and the precipitated precipitate is filtered. After recrystallization from acetonitrile, 6.7-dnmethoxy-1-G4- (L-ethylcarbamoyloxy) -piperidine phthalazine (1.6 g) is obtained in a pale yellow crystal with a melting point of 182-186 s. Found,%: C 59.6; H 6.8; N 15.8 CjgHj 4 ° L Calculated,%: C 60.0; H 6.7; N 15.6 This procedure is repeated using triethylamine instead of the excess of said piperidine; an angshoic result was obtained. Examples 2-37 (table 1 and 2). The following phthalazines were prepared according to Example 1, 1-chloro-6,7-dimethoxyphthalazine and the corresponding MH or 4-substituted piperidine were used as starting materials, Table 1
    Continued table. one
    In parentheses - theoretical value
    in parentheses - theoretical value
    Example 38. Preparation of 1 {4-acetoxypipwrnd mo) -b, 7-dimethyl-oxo-tha-alaine and xssalate. anhydride (1g5 g) and acetic acid (12 ml) coniferous
    table 2
    .
    wKz "Chh Ch
    but
    at 17 o'clock. The coolant solution is then concentrated with water (DO-ml), the neutral is taken up with sodium carbonate to be extracted with chloroform 2X50 M. Chloroform extracts are dried over magnesium sulphate and nitrous oxide, resulting in a dark oily liquid, which is chromatographed on silica gel column (layer size 30x2.0 cm) and eluted with chloroform containing gradually increasing amounts. up to 30% methanol. From 15 collected fractions, 100 ml each, fractions 11-13 are combined and evaporated under vacuum, resulting in an oily product that is triturated with ether (60 ml). After removal The soluble solution is treated with ethereal oxalic acid by filtration and the pH is 4, and the oxalate precipitates. After recrystallization from ethanol, pink crystals of 1- (4-acetoxypiperidino) b, 7-dimethoxyphthalazine mono-oxalate (120 mg) with a melting point of 212-213 ° C.
    Found,%: C 54.1; H 5.5; N 9.7
    Ci-7H, j., N Pd-Sln.04
    Calculated,%: C 54.2; H 5.5; N 10.0
    Example 39. Preparation of 6,7-dimethoxy-1-C4- (2-hydroxypropyl) piperidine phthalazine. 6,7-Dimethoxy-1U4- (2-acetoxypropyl) piperidino phthalazine (1 g) is heated to 90 ° C in a mixture of 5N sodium hydroxide solution (5 ml) and ethanol (5 ml) for 30 hours. Next, the mixture is evaporated under vacuum, and the residue suspended in water (25 ml), from which it is extracted with chloroform (ml). The chloroform extracts are combined, washed with water (20 ml) and evaporated under vacuum, as a result of which: a crude oily product is formed, which solidifies upon trituration with ether (20 ml). Recrystallization from acetonitrile gives b, 7-dimethoxy-1-G4- (2-hydroxypropyl) piperidino phthalazine (400 mg with a melting point of 154-156 ° C.
    Found,%: C 65.2; H 7.6; N 12.6
    c eHjsN 0.03
    Calculated,%: C 65.2; H 7.6; N 12.7. Example 40. Preparation of 6,7-dimethoxy-1- (4-acetonylpiperidino) phthalazine hydrochloride. b, 7-Dimethoxy-1- 4- (2-hydroxypropyl) piperidino phthalazine (1.7 g) is added to a stirred mixture of chromium trioxide (3.5 g), dry methylene chloride (90 ml) and dry pyridine 5.5 g The mixture is stirred under nitrogen for 3 hours and then ammonia is added with a large excess, then the reaction mixture is stirred for another 2 hours. The suspended chromium salts are removed by passing through a short column of silica and then filtered through Hiflo (Hiflo, brand name), covered with a layer of vegetable coal 0.5 cm.
    By evaporation of the clear solution under vacuum, the oxidation product is obtained in the form of a yellowish oily liquid, which then re-dissolves in a minimum amount of ethyl acetate and is treated with an excess amount of ethereal acid chloride solution, resulting in the precipitated hydrochloride. After recrystallization of the salt from ethanol, 6,7-dimethoxy-1- (4-acetonylpiperidino) -phtalazine hydrochloride (0.5 g) is obtained from 1. pl.213214s.
    Found,%: C 58.4; H 6.7; M 11.2. NA)
    Calculated,%: C 5,1; H 6.6; N 11.5.
    Example 41. Preparation of 6,7-dimethoxy-1-4- (N-Norm7Propilkarbamoyloxy) piperidino phthalazine hydrochloride.
    6,7-dimethoxy-1- (4-hydroxypiperidino) phthalazine 0.81 g, normpropyl isocyanate 0.83 g, triethylamine 0.4 ml and dry chloroform 20 ml are heated together to the boiling point, and this temperature is maintained for 10 hours. Next the mixture is cooled, treated with 15 ml of water and the organic layer is separated, washed with 1N. sodium hydroxide solution (10 ml), dried, over magnesium sulphate and evaporated under vacuum, resulting in a yellow oily liquid. It dissolves in a minimal amount of chloroform and is subjected to chromatography on silica (layer size cm). Elution is carried out with chloroform containing gradually increasing amounts of methanol (up to 10%). The first 800 ml of eluent is discarded and 14 CI-fractions of 7C ml are collected, of which with the HELP
    thin-layer chromatography selects the desired fractions. They are combined and evaporated in vacuo to form a yellow oily liquid. This oily liquid is dissolved in a minimum volume of ethyl acetate, diluted with ether (30 ml) and acidified to pH 3 with a saturated ethiolic HCl solution. The precipitated solid is collected and recrystallized from acetonitrile, which results in the formation of 6,7-dimethoxy-1-4 - (N-HOpM.-propylcarbamoyloxy) piperidino phthalazine hydrochloride (0.32 g), m.p. 175-180 ° C.
    Found,%: C 55.3; H 6.5; And 13.8. CfsHibNiO - HCI
    Calculated,%: C 55.5; H 6.6; 13.6.
    Examples 42-46. The following phthalazines are prepared according to Example 41, starting from 1- (3 or 4-hydroxypiperidino) b, 7-dimethoxyphthalazine and the corresponding isocyanate (see table 3).
    -Table 3
    phenyl, di- (C-C4-alkoxy) -phenyl, benzyl, or 2-, 3- or 4-pyridyl
    -f f: ONR R, where R is a hydrogen atom or C, -C4-alkyl, R - C-Cd-a, yl, benzyl or 2-, 3- or 4-pyridyl and 65
    but
    where Y is as defined above, and if Y is a group capable of replacing the Q group, Y is protected with a protective group before the reaction, which is deposited after the reaction, the resulting target products are isolated in free form or as a salt, or necessary, a compound of general formula T, in which Y is hydroxy, is converted to a compound of general formula 1, in which Y is OCONHR, where the values of R are given above, by reacting with an isocyanate, where R OT is different from a hydrogen atom, or to obtain a compound Formula T, in which R is a hydrogen atom, with cyanate sodium or cyanate k.ali in the presence of acid; . or convert a compound of general formula I, where Y is OH, to a compound in which Y. is a lower alkanoyloxy group, by acylation with a lower alkanoic acid anhydride or lower. , alkanoyl chloride or bromide, or convert a compound of the general formula 1, where V is CH “—CH — lower alkyl, into a compound of the general formula 1, in which Y is a group of the formula (lower alkyl)., oxidation with chromium trioxide, and the target product is released. lt Sources of information taken into account in the examination 1. Heterocyclic compounds. Ed. R. Elderfield, tL, M., Foreign literature, 1953, p.515.
    权利要求:
    Claims (1)
    [1]
    Claim
    1. a method of obtaining derivatives
    1- (N-piperidino) -phthalazine of the general formula I ·>. Λ
    R T is a hydrogen atom or C ^ -Cd-alkyl -OCOHHR 6 , where R 6 is C ^ -Cd-alkyl, phenyl, benzyl or 2-, 3- or 4-pyri in which R *
    Υ
    - a hydrogen atom;
    - is in the 3- or 4-position of the piperidine ring and denotes
    -CHqCOR ' 2 , where R 3 is C ^ -Cd-alkyl or C ^ -Cd-alkoxy; „
    -N-COR®, where R 'is Cf-Cd-alkyl, uh
    R 4
    C4-Cd-alkoxyphenyl or benzyloxy and R * is a hydrogen atom or C, -C d-alkyl -N ^ SOq-R 5 , where '' R * is a hydrogen atom * or C4-C4-alkyl and R'-C ^ -Cd-alkyl, 60 phenyl, di- (C4-Cd-alkoxy) -phenyl, beisyl, or 2-, 3- or 4-pyridyl where R 4 is a hydrogen atom or C, -Cd-alkyl, R b is C ^ -Cd-alkyl, benzyl or 2-, 3- or 4-pyridyl and 65 dil;
    -oxy, C ^ -Cd alkanoyloxy or
    C 4 -C alkoxy;
    —C4-C5 — alkyl substituted with an oxy group, C., —C, alkoxy or a group of the formula CONR s r] where R ^ h R 7 are each independently a hydrogen atom or C 1 -Cd alkyl;
    C ^ -Cd alkoxy substituted at any position except d. a carbon atom, an oxy group or a C 4 -Cd alkoxy group, or their salts, characterized in that the phthalazine of the general formula Ιί where Q 1 are chlorine, bromine or iodine atoms ”is reacted with piperidine of the general formula where Y has the meanings indicated above wherein, if Y - group capable to substitute the group G '1, Y before reaction. 15 it is protected with a protecting group, which is removed after the reaction, the obtained target products are isolated in the free form or in the form of a salt, or, if necessary, a compound of the general formula T in which Y is hydroxy is converted into a compound of the general formula T in which Y - OCONHR, where R "values are given above, by reacting with the isocyanate R 6 NCO, where R 6 is other than a hydrogen atom, or to obtain a compound of general formula T in which R 6 is a hydrogen atom with sodium cyanate or potassium cyanate in the presence of acid;
    or converting a compound of general formula T, where U is OH, to a compound in which Y is a lower alkanoyloxy group, by acylation with lower alkanoic acid anhydride or lower alkanoyl chloride or bromide; or convert a compound of General formula I, where Y is CH.-CH is lower alkyl,
    OH to the compound of general formula T, in which Y is a group of the formula —CH ^ —CO (lower alkyl)., By oxidation of trioxide, chromium sieve, and the desired product are isolated. .
    类似技术:
    公开号 | 公开日 | 专利标题
    SU856383A3|1981-08-15|Method of preparing derivatives of 1-|phthalazyl or their salts
    AU599029B2|1990-07-12|Ascorbic acid derivatives, production and use thereof
    US4701459A|1987-10-20|7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
    EP0482208A1|1992-04-29|Pyridazinone derivative
    HU211163A9|1995-10-30|Substituted salicylic acids
    US4370328A|1983-01-25|Cardiac stimulant 1-|phthalazines
    SU865125A3|1981-09-15|Method of preparing imidazole derivatives or thir salts
    US4188391A|1980-02-12|4-[4-|piperidino]quinazoline cardiac stimulants
    US4670434A|1987-06-02|oxyalkylamides useful as cyclic AMP phosphodiesterase inhibitors
    US4990509A|1991-02-05|Sulfonamide anti-arrhythmic agents
    US2540218A|1951-02-06|2-hydroxy-pyridine-n-oxide and process for preparing same
    US5594144A|1997-01-14|Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases
    AT403282B|1997-12-29|3 | -PYRIDAZINONE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
    US5599813A|1997-02-04|Thiazolopyrimidine derivatives
    US4243666A|1981-01-06|4-Amino-2-piperidino-quinazolines
    DE69333285T2|2004-08-26|2-HETEROCYCLIC-5-HYDROXY-1,3-PYRIMIDINE USED AS AN INFLAMMABLE AGENT
    JP2860689B2|1999-02-24|Pyrimidine derivatives
    PT91783B|1995-08-09|PROCESS FOR THE PREPARATION OF {| ALKYL} -1-PYRROLIDINS AND PIPERIDINES
    JP2000198784A|2000-07-18|Optically active piperidine derivative acid addition salt and its production
    JP2931986B2|1999-08-09|Aralkylamine derivatives
    US4005201A|1977-01-25|7-|pyrido|pyridazines
    Taylor et al.1989|1, 3-Dipolar cycloaddition of nitrile oxides with 1, 4-dihydropyridines and conformational analysis of isoxazolo [5, 4-b] pyridines
    GB2171997A|1986-09-10|4-Amino-6,7-dimethoxy-2-Piperazin-1-ylquinazoline derivatives
    US4654349A|1987-03-31|Anti-allergic methods using pyrazolo|pyridines
    US4517365A|1985-05-14|Isocarbostyril derivative
    同族专利:
    公开号 | 公开日
    GR74402B|1984-06-28|
    PL116420B1|1981-06-30|
    DE2824064A1|1978-12-14|
    ZA783183B|1979-06-27|
    DK248078A|1978-12-04|
    IN148482B|1981-03-07|
    SE7806519L|1978-12-04|
    IT1094944B|1985-08-10|
    IN149973B|1982-06-19|
    IN149550B|1982-01-16|
    EG13527A|1981-12-31|
    FI781753A|1978-12-04|
    FR2392986A1|1978-12-29|
    PL113208B1|1980-11-29|
    ES470470A1|1979-09-01|
    FR2392986B1|1982-07-16|
    IL54842A|1982-01-31|
    AR223999A1|1981-10-15|
    IT7824106D0|1978-06-01|
    LU79761A1|1980-01-22|
    AU505373B1|1979-11-15|
    PL207337A1|1979-06-04|
    CA1111850A|1981-11-03|
    GB2000136B|1982-01-06|
    NO781935L|1978-12-05|
    ES478199A1|1980-01-16|
    AT363096B|1981-07-10|
    IL54842D0|1978-08-31|
    GB2000136A|1979-01-04|
    ES478200A1|1980-01-01|
    PT68126A|1978-07-01|
    SU862826A3|1981-09-07|
    DD137355A5|1979-08-29|
    AT362792B|1981-06-10|
    ES478201A1|1980-02-01|
    PL116437B1|1981-06-30|
    AR222013A1|1981-04-15|
    HU179745B|1982-12-28|
    ATA305080A|1980-12-15|
    NZ187453A|1980-12-19|
    BE867727A|1978-12-01|
    JPS5416488A|1979-02-07|
    NL7806016A|1978-12-05|
    US4289772A|1981-09-15|
    JPS5538351B2|1980-10-03|
    ATA400878A|1980-11-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB1094044A|1965-07-12|1967-12-06|Vantorex Ltd|Phthalazine derivatives|
    GB1199768A|1966-10-31|1970-07-22|Pfizer & Co C|Nitrogen Heterocycles and process for their preparation|
    GB1293565A|1969-05-03|1972-10-18|Aspro Nicholas Ltd|Aminophthalazines and pharmaceutical compositions thereof|
    GB1460389A|1974-07-25|1977-01-06|Pfizer Ltd|4-substituted quinazoline cardiac stimulants|US4370328A|1977-11-03|1983-01-25|Pfizer Inc.|Cardiac stimulant 1-phthalazines|
    IL59619D0|1979-03-28|1980-06-30|Pfizer|Phthalazine derivatives,their preparation and pharmaceutical compositions containing them|
    PL135545B1|1980-03-01|1985-11-30|Wyeth John & Brother Ltd|Process for preparing novel derivatives of piperidine|
    GB8320958D0|1983-08-03|1983-09-07|Pfizer Ltd|Quinazoline cardiac stimulants|
    US5001125A|1984-03-26|1991-03-19|Janssen Pharmaceutica N.V.|Anti-virally active pyridazinamines|
    US4882354A|1987-12-16|1989-11-21|Norwich Eaton Pharmaceuticals, Inc.|N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents|
    JP3169188B2|1991-01-31|2001-05-21|杏林製薬株式会社|Carbamic acid derivative and method for producing the same|
    US5300515A|1991-01-31|1994-04-05|Kyorin Pharmaceutical Co., Ltd.|Carbamic acid derivatives and method for preparing the same|
    EP0621267A1|1993-04-07|1994-10-26|Shell Internationale Researchmaatschappij B.V.|Spiropiperidine derivatives and their use as fungicides|
    US5728712A|1995-05-19|1998-03-17|Chiroscience Limited|3,4-disubstituted-phenylsulphonamides and their therapeutic use|
    CA2258079A1|1996-08-20|1998-02-26|Mayu Shibazaki|Remedy for erection failure comprising fused pyridazine compound|
    US20030186963A1|2001-09-14|2003-10-02|Dorwald Florencio Zaragoza|Substituted piperidines|
    EP1539739B1|2002-08-16|2010-11-24|Janssen Pharmaceutica NV|Piperidinyl compounds that selectively bind integrins|
    US20040224986A1|2002-08-16|2004-11-11|Bart De Corte|Piperidinyl targeting compounds that selectively bind integrins|
    US20060019975A1|2004-07-23|2006-01-26|Pfizer Inc|Novel piperidyl derivatives of quinazoline and isoquinoline|
    TW200630337A|2004-10-14|2006-09-01|Euro Celtique Sa|Piperidinyl compounds and the use thereof|
    EP2258357A3|2005-08-26|2011-04-06|Braincells, Inc.|Neurogenesis with acetylcholinesterase inhibitor|
    WO2007025177A2|2005-08-26|2007-03-01|Braincells, Inc.|Neurogenesis by muscarinic receptor modulation|
    CA2625153A1|2005-10-21|2007-04-26|Braincells, Inc.|Modulation of neurogenesis by pde inhibition|
    WO2007134136A2|2006-05-09|2007-11-22|Braincells, Inc.|Neurogenesis by modulating angiotensin|
    EP1942879A1|2005-10-31|2008-07-16|Braincells, Inc.|Gaba receptor mediated modulation of neurogenesis|
    EP1981868A2|2006-01-27|2008-10-22|Pfizer Products Inc.|Aminophthalazine derivative compounds|
    US20100216734A1|2006-03-08|2010-08-26|Braincells, Inc.|Modulation of neurogenesis by nootropic agents|
    WO2007110449A1|2006-03-29|2007-10-04|Euro-Celtique S.A.|Benzenesulfonamide compounds and their use|
    WO2007118853A1|2006-04-13|2007-10-25|Euro-Celtique S.A.|Benzenesulfonamide compounds and their use as blockers of calcium channels|
    TW200812963A|2006-04-13|2008-03-16|Euro Celtique Sa|Benzenesulfonamide compounds and the use thereof|
    EP2026813A2|2006-05-09|2009-02-25|Braincells, Inc.|5 ht receptor mediated neurogenesis|
    EP1900731A1|2006-09-07|2008-03-19|Bayer Schering Pharma Aktiengesellschaft|N--amides as EP2-receptor modulators|
    EP1903037A1|2006-09-07|2008-03-26|Bayer Schering Pharma Aktiengesellschaft|1-aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors|
    US7998971B2|2006-09-08|2011-08-16|Braincells Inc.|Combinations containing a 4-acylaminopyridine derivative|
    US20100184806A1|2006-09-19|2010-07-22|Braincells, Inc.|Modulation of neurogenesis by ppar agents|
    US8399486B2|2007-04-09|2013-03-19|Purdue Pharma L.P.|Benzenesulfonyl compounds and the use thereof|
    CA2695211A1|2007-08-07|2009-02-12|F. Hoffmann-La Roche Ag|Pyrrolidine aryl-ether as nk3 receptor antagonists|
    RU2010108687A|2007-08-22|2011-09-27|Ф.Хоффманн-Ля Рош Аг |Aryl esters of pyrrolidine as antagonists of NK3 receptors|
    WO2009033995A1|2007-09-14|2009-03-19|F. Hoffmann-La Roche Ag|Piperidine derivatives as nk3 receptor antagonists|
    US8765736B2|2007-09-28|2014-07-01|Purdue Pharma L.P.|Benzenesulfonamide compounds and the use thereof|
    US20100216805A1|2009-02-25|2010-08-26|Braincells, Inc.|Modulation of neurogenesis using d-cycloserine combinations|
    AR077014A1|2009-06-19|2011-07-27|Lilly Co Eli|COMPOUND DERIVED FROM FTALAZINE 1,4-DISPOSED, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER|
    US20150119399A1|2012-01-10|2015-04-30|President And Fellows Of Harvard College|Beta-cell replication promoting compounds and methods of their use|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB2358277|1977-06-03|
    [返回顶部]